How to buy Allena Pharmaceuticals stock | $0.89

Allena Pharmaceuticals Inc is a biotechnology business based in the US. Allena Pharmaceuticals shares (ALNA) are listed on the NASDAQ and all prices are listed in US Dollars. Allena Pharmaceuticals employs 47 staff and has a market cap (total outstanding shares value) of 0.00.

Allena Pharmaceuticals stock price (NASDAQ: ALNA)

Use our graph to track the performance of ALNA stocks over time.

Allena Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-11.

Latest market close	$0.89
52-week range	$0.75 - $2.24
50-day moving average	$0.96
200-day moving average	$1.10
Wall St. target price	$6.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.92

Buy Allena Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Allena Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Allena Pharmaceuticals price performance over time

Historical closes compared with the close of $0.89 from 2021-10-14

1 week (2021-10-05)	N/A
1 month (2021-09-16)	-7.72%
3 months (2021-07-16)	5.33%
6 months (2021-04-16)	-20.54%

1 year (2020-10-16)	-42.58%
2 years (2019-10-16)	-81.42%
3 years (2018-10-16)	10.71
5 years (2016-10-12)	N/A

Allena Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-90.5%
Return on equity TTM	-286.5%
Profit margin	0%
Book value	$0.21
Market capitalisation	$66.5 million

TTM: trailing 12 months

Shorting Allena Pharmaceuticals shares

There are currently 2.4 million Allena Pharmaceuticals shares held short by investors – that's known as Allena Pharmaceuticals's "short interest". This figure is 24.6% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Allena Pharmaceuticals shares can be evaluated.

Allena Pharmaceuticals's "short interest ratio" (SIR)

Allena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Allena Pharmaceuticals shares currently shorted divided by the average quantity of Allena Pharmaceuticals shares traded daily (recently around 1.1 million). Allena Pharmaceuticals's SIR currently stands at 2.18. In other words for every 100,000 Allena Pharmaceuticals shares traded daily on the market, roughly 2180 shares are currently held short.

However Allena Pharmaceuticals's short interest can also be evaluated against the total number of Allena Pharmaceuticals shares, or, against the total number of tradable Allena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allena Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Allena Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0301% of the tradable shares (for every 100,000 tradable Allena Pharmaceuticals shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Allena Pharmaceuticals.

Find out more about how you can short Allena Pharmaceuticals stock.

Allena Pharmaceuticals share dividends

We're not expecting Allena Pharmaceuticals to pay a dividend over the next 12 months.

Allena Pharmaceuticals share price volatility

Over the last 12 months, Allena Pharmaceuticals's shares have ranged in value from as little as $0.75 up to $2.24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allena Pharmaceuticals's is 2.1483. This would suggest that Allena Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Allena Pharmaceuticals overview

Allena Pharmaceuticals, Inc. , a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts. .

Frequently asked questions

What percentage of Allena Pharmaceuticals is owned by insiders or institutions?
Currently 1.544% of Allena Pharmaceuticals shares are held by insiders and 30.156% by institutions. How many people work for Allena Pharmaceuticals?
Latest data suggests 47 work at Allena Pharmaceuticals. When does the fiscal year end for Allena Pharmaceuticals?
Allena Pharmaceuticals's fiscal year ends in December. Where is Allena Pharmaceuticals based?
Allena Pharmaceuticals's address is: One Newton Executive Park, Newton, MA, United States, 02462 What is Allena Pharmaceuticals's ISIN number?
Allena Pharmaceuticals's international securities identification number is: US0181191075 What is Allena Pharmaceuticals's CUSIP number?
Allena Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 018119107